Dimensional Fund Advisors LP Sells 233,118 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Dimensional Fund Advisors LP decreased its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 14.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,329,065 shares of the biopharmaceutical company’s stock after selling 233,118 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Agios Pharmaceuticals were worth $43,674,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in AGIO. Franklin Resources Inc. purchased a new stake in shares of Agios Pharmaceuticals in the third quarter valued at approximately $1,499,000. Nordea Investment Management AB lifted its holdings in shares of Agios Pharmaceuticals by 3.6% in the 4th quarter. Nordea Investment Management AB now owns 220,569 shares of the biopharmaceutical company’s stock worth $7,191,000 after buying an additional 7,593 shares during the period. Contravisory Investment Management Inc. purchased a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth $222,000. Inspire Investing LLC grew its position in shares of Agios Pharmaceuticals by 34.2% during the 4th quarter. Inspire Investing LLC now owns 12,384 shares of the biopharmaceutical company’s stock worth $407,000 after buying an additional 3,156 shares in the last quarter. Finally, KBC Group NV raised its holdings in shares of Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 611 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Scotiabank lowered their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating for the company in a research note on Friday. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. Finally, HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective for the company. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $56.00.

Agios Pharmaceuticals Stock Down 2.7 %

NASDAQ AGIO opened at $30.10 on Friday. The firm has a market cap of $1.74 billion, a PE ratio of 2.65 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58. The company has a 50 day moving average price of $29.81 and a 200 day moving average price of $37.80.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the business’s stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now owns 149,220 shares of the company’s stock, valued at approximately $3,864,798. The trade was a 4.78 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.93% of the stock is currently owned by company insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.